Receive our newsletter – data, insights and analysis delivered to you
  1. Deals Analysis
March 27, 2021

Medical Devices industry venture financing deals total $811.82m in US in February 2021

Total medical devices industry venture financing deals worth $811.82m were announced in the US in February 2021, led by $105m venture financing of Truvian Sciences, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

The value marked a decrease of 28.8% over the previous month of $1.14bn and a drop of 4.6% when compared with the last 12-month average of $851.05m.

The US held a 66.54% share of the global medical devices industry venture financing deal value that totalled $1.22bn in February 2021.

In terms of venture financing deal activity, the US recorded 40 deals during February 2021, marking a decrease of 20.00% over the previous month and a drop of 27.27% over the 12-month average.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

US medical devices industry venture financing deals in February 2021: Top deals

The top five medical devices industry venture financing deals accounted for 52.5% of the overall value during February 2021.

The combined value of the top five medical devices venture financing deals stood at $426m, against the overall value of $811.82m recorded for the month.

The top five medical devices industry venture financing deals of February 2021 tracked by GlobalData were:

1) DNS Capital, General Catalyst Partners, Glen Tullman, GreatPoint Ventures, TYH Ventures, Wasson Enterprise and Wittington Ventures’ $105m venture financing of Truvian Sciences

2) The $103m venture financing of Personal Genome Diagnostics by Catalio Capital Management, Cowen Healthcare Investments, Innovatus Capital Partners, Kern Capital Management, New Enterprise Associates, Northpond Ventures, PFM Health Sciences, Rock Springs Capital Management, Sands Capital Management, Vensana Capital and Windham Venture Partners

3) Altium Capital, Axiom Associates, Colle Capital Partners, GV Management Co, Huamin Investment Management and Nextrans’ $90m venture financing of Hyperfine Research

4) The $68m venture financing of Syapse by Ally Bridge Group and Northpond Ventures

5) Catalio Capital Management, Dexcel Pharma, Duquesne Family Office, Schusterman Family Investments, TLV Partners and Viola Ventures’ venture financing of Immunai for $60m.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU